Preclinical rationale for Herceptin treatment beyond progression in HER2-positive breast cancer
Established chemotherapy resistance mechanisms. Impaired drug uptakeActive drug efflux, eg by ABC transporters (P-glycoprotein, MDR2, BCRP, MRP1-6 etc)Enhanced drug metabolism, eg by P450 enzymesAlterations of intracellular target, eg tubulinUpregulation of DNA repair in tumour cellsUpregulati
488 views • 17 slides